Debt-to-equity of Cogent Biosciences, Inc. from 30 Sep 2018 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Cogent Biosciences, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 31 Dec 2025.
Cogent Biosciences, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 46%, a 152% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Cogent Biosciences, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	46%	+28%	+152%	31 Dec 2025
Q3 2025	41%	+23%	+136%	30 Sep 2025
Q2 2025	34%	+18%	+114%	30 Jun 2025
Q1 2025	23%	+7.1%	+46%	31 Mar 2025
Q4 2024	18%	+1.5%	+8.7%	31 Dec 2024
Q3 2024	17%	+1.2%	+7.4%	30 Sep 2024
Q2 2024	16%	+0.89%	+5.8%	30 Jun 2024
Q1 2024	15%	-0.43%	-2.7%	31 Mar 2024
Q4 2023	17%	+2.5%	+17%	31 Dec 2023
Q3 2023	16%	+3.6%	+29%	30 Sep 2023
Q2 2023	15%	+4.2%	+38%	30 Jun 2023
Q1 2023	16%	+7.2%	+82%	31 Mar 2023
Q4 2022	14%	+7.1%	+97%	31 Dec 2022
Q3 2022	12%	+5.4%	+77%	30 Sep 2022
Q2 2022	11%	+0.86%	+8.4%	30 Jun 2022
Q1 2022	8.7%	-5%	-36%	31 Mar 2022
Q4 2021	7.4%	-18%	-71%	31 Dec 2021
Q3 2021	7%	-115%	-94%	30 Sep 2021
Q2 2021	10%	-58%	-85%	30 Jun 2021
Q1 2021	14%	-58%	-81%	31 Mar 2021
Q4 2020	25%	-47%	-65%	31 Dec 2020
Q3 2020	122%	+57%	+86%	30 Sep 2020
Q2 2020	68%	+16%	+29%	30 Jun 2020
Q1 2020	71%	+28%	+63%	31 Mar 2020
Q4 2019	73%	-1.8%	-2.4%	31 Dec 2019
Q3 2019	65%	-233%	-78%	30 Sep 2019
Q2 2019	53%			30 Jun 2019
Q1 2019	44%			31 Mar 2019
Q4 2018	74%			31 Dec 2018
Q3 2018	298%			30 Sep 2018

* An asterisk sign (*) next to the value indicates that the value is likely invalid.